Gormonal'naya kontratseptsiya i serdechno-sosudistyy risk


Cite item

Full Text

Abstract

References

  1. Гинекология. Национальное руководство Под ред. В.И.Кулакова, Г.М.Савельевой, И.Б.Манухина. М.: ГЭОТАР-Медиа, 2009; с. 355.
  2. Chandra AMG, Mosher WD, Abma JC, Jones J. Fertility, family planning, and reproductive health of U.S. women: data from the 2002 National Survey of Family Growth. National Center for Health Statistics. Vital Health Stat 2005; 23: 19-21.
  3. Schindler AE. Non-contraceptive benefits of hormonal contraceptives. Minerva Ginecol 2010; 62 (4): 319-29.
  4. Solomon CG et al. Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE study. J Clin Endocrinol Metab 2002; 87 (5): 2013-7.
  5. Bairey Merz CN, Johnson BD, Sharaf BL et al. WISE Study Group. Menstrual cycle irregularity and risk for future cardiovascular disease. J Am Coll Cardiol 2003; 41 (3): 413-9.
  6. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340 (23): 1801-11.
  7. Adams MR, Kaplan JR, Manuck SB et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis 1990; 10 (6): 1051-7.
  8. Margolis KL, Adami HO, Luo J et al. A prospective study or oral contraceptive use and risk of myocardial infarction among Swedish women. Fertil Steril 2007; 88: 310-6.
  9. Shufelt CL, Bairey Merz CN. Contraceptive hormone use and cardiovascular disease. J Am Coll Cardiol 2009; 53 (3): 221-31.
  10. Lentz: Comprehensive Gynecology, 6th ed. Mosby, 2012; p. 225-6.
  11. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000; 62 (1): 29-38.
  12. Кардиология. Национальное руководство: краткое издание. Под ред. Ю.Н.Беленкова, Р.Г.Оганова. М.: ГЭОТАР-Медиа, 2012; с. 40.
  13. Williams JK, Kim YD, Adams MR et al. Effects of estrogen on cardiovascular responses of premenopausal monkeys. J Pharm Exp Ther 1994; 271 (2): 671-6.
  14. Kaplan JR, Adams MR, Anthony MS et al. Dominant social status and contraceptive hormone treatment inhibit atherogenesis in premenopausal monkeys. Arterioscler Thromb Vasc Biol 1995; 15 (12): 2094-100.
  15. Wagner JD, Clarkson TB, St Clair RW et al. Estrogen and progesterone replacement therapy reduces low density lipoprotein accumulation in the coronary arteries of surgically postmenopausal cynomolgus monkeys. J Clin Invest 1991; 88 (6): 1995-2002.
  16. Adams MR, Williams JK, Clarkson TB, Jayo MJ. Effects of oestrogens and progestogens on coronary atherosclerosis and osteoporosis of monkeys. Baillieres Clin Obstet Gynaecol 1991; 5 (4): 915-34.
  17. Adams MR, Anthony MS, Manning JM et al. Low-dose contraceptive estrogen-progestin and coronary artery atherosclerosis of monkeys. Obstet Gynecol 2000; 96 (2): 250-5.
  18. Jones DR, Schmidt RJ, Pickard RT et al. Estrogen receptor-mediated repression of human hepatic lipase gene transcription. J Lipid Res 2002; 43 (3): 383-91.
  19. Speroff L, De Cherney A. Evaluation of a new generation of oral contraceptives. The Advisory Board for the New Progestins. Obstet Gynecol 1993; 81 (6): 1034-47.
  20. Endrikat J, Klipping C, Cronin M, Gerlinger C, Ruebig A, Schmidt W, Düsterberg B. An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 microg ethinyl estradiol and 100 microg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables. Contraception 2002; 65 (3): 215-21.
  21. Barkfeldt J, Virkkunen A, Dieben T. The effects of two progestogen-only pills containing either desogestrel (75 microg/day) or levonorgestrel (30 microg/day) on lipid metabolism. Contraception 2001; 64 (5): 295-9.
  22. Dubey RK, Oparil S, Imthurn B, Jackson EK. Sex hormones and hypertension. Cardiovasc Res 2002; 53 (3): 688-708.
  23. Narkiewicz K, Graniero GR, D'Este D et al. Ambulatory blood pressure in mild hypertensive women taking oral contraceptives. A case-control study. Am J Hypertens 1995; 8 (3): 249-53.
  24. Cardoso F, Polónia J, Santos A et al. Low-dose oral contraceptives and 24-hour ambulatory blood pressure. Int J Gynaecol Obstet 1997; 59 (3): 237-43.
  25. Suthipongse W, Taneepanichskul S. An open-label randomized comparative study of oral contraceptives between medications containing 3 mg drospirenone/30 microg ethinylestradiol and 150 microg levonogestrel/30 microg ethinylestradiol in Thai women. Contraception 2004; 69 (1): 23-6.
  26. Kay CR. The Royal College of General Practitioners' Oral Contraception Study: some recent observations. Clin Obstet Gynaecol 1984; 11 (3): 759-86.
  27. Chasan-Taber L, Willett WC, Stampfer MJ et al. A prospective study of oral contraceptives and NIDDM among U.S. women. Diabetes Care 1997; 20 (3): 330-5.
  28. Kim C, Siscovick DS, Sidney S et al. CARDIA Study. Oral contraceptive use and association with glucose, insulin, and diabetes in young adult women: the CARDIA Study. Coronary Artery Risk Development in Young Adults. Diabetes Care 2002; 25 (6): 1027-32.
  29. Kjos SL, Shoupe D, Douyan S et al. Effect of low-dose oral contraceptives on carbohydrate and lipid metabolism in women with recentgestational diabetes: results of a controlled, randomized, prospective study. Am J Obstet Gynecol 1990; 163 (6 Pt 1): 1822-7.
  30. Robbins J, Nelson JC, Rautaharju PM, Gottdiener JS. The association between the length of the QT interval and mortality in the Cardiovascular Health Study. Am J Med 2003; 115 (9): 689-94.
  31. Liu XK, Katchman A, Whitfield BH et al. In vivo androgen treatment shortens the QT interval and increases the densities of inward and delayed rectifier potassium currents in orchiectomized male rabbits. Cardiovasc Res 2003; 57 (1): 28-36.
  32. Odening KE, Choi BR, Liu GX et al. Estradiol promotes sudden cardiac death in transgenic long QT type 2 rabbits while progesterone is protective. Heart Rhythm 2012; 9 (5): 823-32.
  33. Seth R, Moss AJ, McNitt S et al. Long QT syndrome and pregnancy. J Am Coll Cardiol 2007; 49 (10): 1092-8.
  34. Cheng J. Evidences of the gender-related differences in cardiac repolarization and the underlying mechanisms in different animal species and human. Fundam Clin Pharmacol 2006; 20 (1): 1-8.
  35. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005; 352 (12): 1223-36.
  36. Clarkson TB, Anthony MS, Klein KP. Hormone replacement therapy and coronary artery atherosclerosis: the monkey model. Br J Obstet Gynaecol 1996; 103 (Suppl. 13): 53-7.
  37. Merz CN, Johnson BD, Berga S et al. WISE Study Group. Past oral contraceptive use and angiographic coronary artery disease in postmenopausal women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. Fertil Steril 2006; 85 (5): 1425-31.
  38. Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel. Contraception 2006; 73 (6): 566-70.
  39. Magnusdóttir EM, Bjarnadóttir RI, Onundarson PT et al. The contraceptive vaginal ring (NuvaRing) and hemostasis: a comparative study. Contraception 2004; 69 (6): 461-7.
  40. Sitruk-Ware R, Plu-Bureau G, Menard J et al. Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover study. J Clin Endocrinol Metab 2007; 92 (6): 2074-9.
  41. World Health Organization. Selected Practice Recommendations for Contraceptive Use [Second Edition]. http://www.who.int./reproductive-health/publications/spr/2004
  42. Gerstman BB, Piper JM, Tomita DK et al. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991; 133 (1): 32-7.
  43. Rosendaal FR, Reitsma PH. Genetics of venous thrombosis. J Thromb Haemost 2009; 7 (Suppl. 1): 301-4.
  44. Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol 2007; 44 (2): 62-9.
  45. World Health Organization. Medical Eligibility Criteria for Contraceptive Use, 4th edition. Geneva: WHO, 2009. http://www.who. int/reproductive-health/publications/ mec/family_planning/ 9789241563888/en/index.html
  46. Mileikowsky GN, Nadler JL, Huey F et al. Evidence that smoking alters prostacyclin formation and platelet aggregation in women who use oral contraceptives. Am J Obstet Gynecol 1988; 159 (6): 1547-52.
  47. Rångemark C, Benthin G, Granström EF et al. Tobacco use and urinary excretion of thromboxane A2 and prostacyclin metabolites in women stratified by age. Circulation 1992; 86 (5): 1495-500.
  48. Fruzzetti F, Ricci C, Fioretti P. Haemostasis profile in smoking and nonsmoking women taking low-dose oral contraceptives. Contraception 1994; 49 (6): 579-92.
  49. Van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP et al. Effects of oestrogen dose and progestogen type on venous thrombotic risk associated with oral contraceptives: results of the MEGA case-control study. BMJ 2009; 339: b2921.
  50. Lidegaard O, Edström B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 2002; 65 (3): 187-96.
  51. Jick H, Jick SS, Gurewich V et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346 (8990): 1589-93.
  52. Kemmeren JM, Algra A, Meijers JC et al. Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial. Blood 2004; 103 (3): 927-33.
  53. Schindler AE. Differential effects of progestins on hemostasis. Maturitas 2003; 46 (Suppl. 1): S31-7.
  54. Lewis MA. The epidemiology of oral contraceptive use: a critical review of the studies on oral contraceptives and the health of young women. Am J Obstet Gynecol 1998; 179 (4): 1086-97.
  55. Spitzer WO. Data from transnational study of oral contraceptives have been misused. BMJ 1995; 311 (7013): 1162.
  56. Corson SL. Increased risk from third-generation progestogens: fuzzy logic or fuzzy science? J Reprod Med 1996; 41 (9): 711-2.
  57. Brito MB, Nobre F, Vieira CS. Hormonal contraception and cardiovascular system. Arq Bras Cardiol 2011; 96 (4): e81-9.
  58. Suissa S, Spitzer WO, Rainville B et al. Recurrent use of newer oral contraceptives and the risk of venous thromboembolism. Hum Reprod 2000; 15 (4): 817-21.
  59. http://www.fda.gov/Drugs/DrugSafety/ucm299305.htm
  60. Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med 2004; 164 (18): 1965-76.
  61. Conard J, Plu-Bureau G, Bahi N et al. Progestogen-only contraception in women at high risk of venous thromboembolism. Contraception 2004; 70 (6): 437-41.
  62. Rosendaal FR, van Hylckama Vlieg A, Tanis BC, Helmerhorst FM. Estrogens, progestogens and thrombosis. J Thromb Haemost 2003; 1 (7): 1371-80.
  63. Girolami A, Tezza F, Allemand E, Girolami B. Arterial thrombosis and drospirenone-containing pill (Yasmin). Is the pill to be absolutely avoided by women who smoke? J Thromb Thrombolysis 2008; 26 (2): 163-4.
  64. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1996; 348 (9026): 505-10.
  65. Tanis BC, van den Bosch MA, Kemmeren JM et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001; 345 (25): 1787-93.
  66. Stampfer MJ, Willett WC, Colditz GA et al. Past use of oral contraceptives and cardiovascular disease: a meta-analysis in the context of the Nurses' Health Study. Am J Obstet Gynecol 1990; 163 (1 Pt 2): 285-91.
  67. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1997; 349 (9060): 1202-9.
  68. Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: A meta-analysis. JAMA 2000; 284 (1): 72-8.
  69. Heinemann LA, Lewis MA, Spitzer WO et al. Thromboembolic stroke in young women. A European case-control study on oral contraceptives. Transnational Research Group on Oral Contraceptives and the Health of Young Women. Contraception 1998; 57 (1): 29-37.
  70. Kemmeren JM, Tanis BC, van den Bosch MA et al. Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke 2002; 33 (5): 1202-8.
  71. Edlow AG, Bartz D. Hormonal contraceptive options for women with headache: a review of the evidence. Rev Obstet Gynecol 2010; 3 (2): 55-65.
  72. Kase NG. Impact of hormone therapy for women aged 35 to 65 years, from contraception to hormone replacement. Gend Med 2009; 6 (Suppl. 1): 37-59.
  73. Maguire K, Westhoff C. The state of hormonal contraception today: established and emerging noncontraceptive health benefits. Am J Obstet Gynecol 2011; 205 (Suppl. 4): S4-8.
  74. Национальные медицинские критерии приемлемости методов контрацепции. Адаптированный документ «Медицинские критерии приемлемости использования методов контрацепции ВОЗ. 4-е изд. 2009. М., 2012. http://www.ifhealth.ru/InFo-data/item_033/file_0002016.pdf

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-63961 от 18.12.2015.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies